There is a huge boom in the newfound 'GLP-1 supplements' industry, and New Zealander CaloCurb is taking advantage, seeing 400% to 600% growth per quarter. They are now in the middle of their fourth, and largest, human trial - but will strong clinical results be enough to capture the market?
It took little over 40 Opentrons robots to provide the majority of COVID-19 testing for the city of New York - 15 million people. Top-tier investors have piled in, will their bets pay off in 2025?
Lexicon has been discovering new genetic science since the Human Genome Project. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this summer and has plans to make history.
